The clinical importance of NAbs in multiple sclerosis therapy has been well documented. In a study entitled "Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: Experience during the first three years,"² researchers established several key points. They are the following:

• NAbs develop early, after 6-18 months of treatment
• NAb positive patients had a significantly higher (p<0.05) relapse rate
• the number of enlarging mri lesions was significantly greater in nab positive patients in second and third years than it was in nab negative patients
• mri lesion burden was lower than placebo in nab negative patients and was the same as placebo in nab positive patients

nab activity has been measured in the betaseron^® and Avonex^® clinical trials. Our next session will review evidence of neutralizing antibody (NAb) responses in the Betaseron and Avonex trials.

End of Session I. Thank you for participating. Please look for an email announcing Session II: Incidence and Biological Significance of NAbs, in two weeks.

Avonex is a registered trademark of Biogen, Inc.
Betaseron is a registered trademark of Berlex Laboratories, Inc.

1 2 3 4 5 Your understanding of the disease or condition How you will diagnose patients with this disorder How you will explain the disease or condition to patients and their families None of the above Breaking news in genetics Dementias Epilepsy Mitochondrial disorders Movement disorders Multiple sclerosis Neuromuscular disorders Pediatric disorders

 

Biological Effects of NAbs Back

NAbs Main Menu Back

Current NeuroCAST | NeuroCAST Library | Contact Us | Athena Diagnostics | LabCAST™ | Sign Up | Home

©, Athena Diagnostics, Inc. All Rights Reserved. Internet Site Notice / Disclaimer Form Use of this site is subject to the Internet Site Notice/Disclaimer Form, which you are urged to read prior to proceeding.

Designed and Developed by embarc.